As someone with a strong pattern of hereditary breast/ovarian cancer in my family, it’s safe to say that I follow breast cancer news closely. Last month, there was big news from NCI about a study looking at tamoxifen and raloxifene for breast cancer prevention. Many trumpeted the summary findings — “raloxifene is as effective, with fewer side effects!” — but with studies like these, the devil lies in the details.
Denise Grady of the NYTimes dived into these details, and she breaks them down for us in her “ second opinion ” piece. This is the real news. Women making decisions about treating and preventing breast cancer are faced with a complex challenge of weighing risks, benefits, side effects, and peace of mind. Understanding the real details of your options — and figuring out what they mean to you, personally, can make all the difference in what you decide.